Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Non-randomized Study of a Atezolizumab (MPDL3280A) in Combination With Carboplatin Plus Pemetrexed in Patients Who Are Chemotherapy-naïve and Have Stage IV Non-squamous Non-small Cell Lung Cancer Twith Asymptomatic Brain Metastasis

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03526900
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:08.828659+00:00
Published At
2024-10-09T00:00:00+00:00
Record Updated At
2024-10-09
Results Posted At
2024-10-09
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Non-small Cell Lung Cancer Stage IV"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-10-09"
protocolSection.identificationModule.nctId
"NCT03526900"
protocolSection.identificationModule.officialTitle
"Phase II Non-randomized Study of a Atezolizumab (MPDL3280A) in Combination With Carboplatin Plus Pemetrexed in Patients Who Are Chemotherapy-na\u00efve and Have Stage IV Non-squamous Non-small Cell Lung Cancer Twith Asymptomatic Brain Metastasis"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2024-10-09"

Study condition terms

  • Non-small Cell Lung Cancer Stage IV (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.